Who makes Lyumjev with 50% basal rate reduction?

Lyumjev with 50% basal rate reduction is developed by Eli Lilly and Company.

What development phase is Lyumjev with 50% basal rate reduction in?

Lyumjev with 50% basal rate reduction is in Phase 1.

Last reviewed 2026-05-14 · How we verify

Lyumjev with 50% basal rate reduction

Eli Lilly and Company · Phase 1 active Small molecule

At a glance

Generic name	Lyumjev with 50% basal rate reduction
Also known as	LY900014
Sponsor	Eli Lilly and Company
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Lyumjev with 50% basal rate reduction CI brief — competitive landscape report
Lyumjev with 50% basal rate reduction updates RSS · CI watch RSS
Eli Lilly and Company portfolio CI